Our fully integrated protein manufacturing services covers all needs from initial process development to manufacturing at research, HQ and GMP grade.

Success of Gene and Cell Therapies is dependent on efficient production of viral vectors that require optimized transfection reagents and viral vector engineering
RNA/DNA in vivo delivery is the most powerful alternative to viral vectors for nucleic acid-based therapies. They offer substantial advantages in terms of reliability,safety and costs for nucleic-acid based therapies
Optimised plasmid engineering and specific transfection reagents are key to enable protein expression in a wide range of adherent and suspension mammalian cell types